Why I gave taking antidepressants a second chance with NMOSD
Although taking antidepressants years ago didn't help her mood, columnist Jennifer V. recently decided to give the treatment another try.| Neuromyelitis News
Although taking antidepressants years ago didn't help her mood, columnist Jennifer V. recently decided to give the treatment another try.| Neuromyelitis News
Ultomiris safely and effectively reduces relapse risk in complex NMOSD cases and may be safe in combination with rituximab for short periods.| Neuromyelitis News
Using noninvasive eye scans may help clinicians determine if patients have NMOSD or MS, particularly in early disease stages, a study found.| Neuromyelitis News
A review of nearly 100 articles found that muscle problems are relatively common in NMOSD, affecting more than one-third of patients.| Neuromyelitis News
The gut hormone GLP-1 may drive brain inflammation in NMOSD patients, leading to nausea, vomiting, or hiccups, called area postrema syndrome.| Neuromyelitis News
Ultomiris, an approved infusion therapy for neuromyelitis optica spectrum disorder, is closer to being eligible for reimbursement in Canada.| Neuromyelitis News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Neuromyelitis News
Over a recent concert weekend, columnist Jennifer V. and a U.S. friend bonded over the similarities between their cases of NMOSD and MOGAD.| Neuromyelitis News
Nearly all adults with neuromyelitis optica spectrum disorder NMOSD) experience headaches, especially migraines, a study in Iran shows.| Neuromyelitis News
A study linked late-onset neuromyelitis optica spectrum disorder to worse recovery from relapses and faster disability progression.| Neuromyelitis News
Since her NMOSD diagnosis, columnist Jennifer V. has found routines crucial for distinguishing between bad days and signs of a flare-up.| Neuromyelitis News
For columnist Jennifer V., telehealth appointments have made care more accessible, but some things just can't be done virtually, she says.| Neuromyelitis News
Rituximab and mycophenolate mofetil may offer the most effective off-label alternatives for NMOSD patients, according to a study.| Neuromyelitis News
Patricia Inacio is a science writer for Neuromyelitis News with a PhD in cell biology. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Margarida Maia is a science writer for Neuromyelitis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
NMOSD patients who are positive for the anti-AQP4 antibodies were more likely to have other autoimmune diseases, a study in Argentina shows.| Neuromyelitis News
A new predictive model to identify neuromyelitis optica spectrum disorder patients at a higher risk of relapse was found accurate in a study.| Neuromyelitis News
Marta Figueiredo is a science writer for Neuromyelitis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.| Neuromyelitis News
Living with NMOSD and its resulting disability can make it hard to find and keep employment, a new U.S. study highlights.| Neuromyelitis News
CAR T-cells are able to rapidly eliminate disease-driving immune cells in people with neuromyelitis optica spectrum disorder, or NMOSD.| Neuromyelitis News
A family of molecules that can influence immune activity may spot neuromyelitis optica spectrum disorder in people, serving as biomarkers.| Neuromyelitis News
Nearly all clinicians (88%) in a U.S. survey have prescribed approved NMOSD treatments for their patients with anti-AQP4 antibodies.| Neuromyelitis News
Infections of shingles and cold sores were found to be associated with AQP4 antibody-positive neuromyelitis optica spectrum disorder.| Neuromyelitis News
Depression, anxiety, and sleep disturbances are common among patients with neuromyelitis optica spectrum disorder, a new meta-analysis shows.| Neuromyelitis News
Columnist Candice Galvan shares how she came to realize that to better care for her daughter, she needed to protect her own mental health.| Neuromyelitis News
In her debut column for "The Beginner's Guide to Walking," Jennifer van Amerom describes the role music played in her NMOSD diagnosis.| Neuromyelitis News
Columnist Jennifer Van Amerom knows that reducing stress is a step in the right direction, but she has her own ideas about how to do it.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
NMOSD may begin to manifest as hard-to-treat nausea, vomiting, or hiccups — a condition called area postrema syndrome — delaying a diagnosis.| Neuromyelitis News
NMOSD patients who have had only one relapse tend to underestimate their future relapse risk, but this pattern changes with more relapses, a study finds.| Neuromyelitis News
Marisa Wexler is a senior science writer for Neuromyelitis News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Lindsey Shapiro is a science writer for Neuromyelitis News with a PhD in neuroscience. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Taking ginseng tablets twice a day for three months lessened fatigue in people with NMOSD, a placebo-controlled Phase 3 trial found.| Neuromyelitis News
Rituximab was more efficient at preventing relapses than oral immunosuppressive therapies in a racially diverse group of people with NMOSD.| Neuromyelitis News
Three weeks of low-dose rituximab was found to prevent relapses and disability progression in NMOSD patients, without serious side effects.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
Steve Bryson is a science writer for Neuromyelitis News with a PhD in biochemistry. He covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Sex ratio and age at onset among NMOSD patients are influenced by the proportion of cases with anti-AQP4 antibodies, a review study found.| Neuromyelitis News
What others may see as mood swings, columnist Jennifer van Amerom argues, are often reactions to trauma or treatment.| Neuromyelitis News
Neuromyelitis optica spectrum disorder patients whose first symptoms affect the brainstem are often misdiagnosed and have more relapses, a study finds.| Neuromyelitis News
Immunosuppressive therapy is safe and was found to significantly reduce relapses in elderly patients with late-onset NMOSD, per a study.| Neuromyelitis News
After a series of plasma exchange sessions, columnist Jennifer van Amerom is hoping her vision fully returns to normal.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
Career changes, new home hunts, and symptom flares are a lot to handle, says columnist Jennifer van Amerom, who's juggling life and NMOSD.| Neuromyelitis News
In patients treated with Enspryng, researchers found the proportions of B-cells was unchanged, suggesting it altered their characteristics.| Neuromyelitis News
Uplizna safely provided sustained disease control for NMOSD patients, according to final data from a Phase 2/3 clinical trial.| Neuromyelitis News
